Longitudinal study of CAR-T cell therapy in patients with blood cancers
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
This study looks at how well CAR-T cell therapy works for Chinese patients with blood cancers by gathering information from those who have already received this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06607289 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to investigate the effectiveness of CAR-T cell therapy in Chinese patients diagnosed with hematological malignancies. It will collect patient-level data from a consortium of Phase IV clinical trials and real-world studies to create a comprehensive cohort. The study will include patients who have received CAR-T cell therapy and are part of an existing longitudinal cohort focused on hematological diseases. The goal is to better understand the outcomes and impacts of this innovative treatment approach.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with clinically diagnosed hematological malignancies who have undergone CAR-T cell therapy.
Not a fit: Patients who do not have hematological malignancies or have not received CAR-T cell therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of CAR-T cell therapy for patients with blood cancers.
How similar studies have performed: Other studies have shown promising results with CAR-T cell therapy in hematological malignancies, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinically diagnosed hematologic malignancies * Patients treated with CAR-T cell therapy * Signed the informed consent form
Where this trial is running
Tianjin, Tianjin Municipality
- Institute of Hematology & Blood Diseases Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.